Gilead Sciences, Inc.

Gilead Sciences Inc has agreed to pay $97 million to resolve claims that it illegally used a foundation as a conduit to pay the copays of thousands of Medicare patients taking Gilead's pulmonary arterial hypertension drug Letairis, the Justice Department said on Wednesday...

* CANADA HAS SIGNED AN AGREEMENT FOR AN EXTRA 14 MILLION DOSES OF POTENTIAL MODERNA COVID-19 VACCINE

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.

Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.

Shares of Gilead Sciences Inc <GILD.O> rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc <IMMU.O>.

Shares of Gilead Sciences Inc fell nearly 2% on Monday as investors questioned the steep premium the U.S. drugmaker was willing to pay for Immunomedics Inc.

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Gilead Sciences Inc <GILD.O> is nearing a deal to buy biopharmaceutical company Immunomedics Inc <IMMU.O> for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as need for the costly antiviral wanes, the Department of Health and Human Services (HHS) confirmed on Friday.

U.S. hospitals have turned down about a third of their allocated supplies of the COVID-19 drug remdesivir since July as need for the costly antiviral wanes, according to unpublished government statistics provided to Reuters by a U.S. pharmacists' group.

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc, could charge up to $10,000 for the treatment.

Gilead Inc <GILD.O> said on Friday the U.S. Food and Drug Administration expanded the emergency use authorization of its experimental antiviral COVID-19 treatment, remdesivir, to allow its use in all hospitalized COVID-19 patients.

The U.S. Food and Drug Administration could update its emergency use authorization for Gilead Sciences Inc's <GILD.O> drug remdesivir to include patients hospitalized with moderate COVID-19, despite mixed trial results, the company's top research executive said on Friday.

Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc's remdesivir, but a 10-day course did not show a benefit and the drug did not significantly shorten hospital stays, according to new data.

Shares of Gilead Sciences <GILD.O> fell 3% after the U.S. Food and Drug Administration declined to approve its experimental rheumatoid arthritis treatment, a major setback for one of the drugmaker's important products.